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Abstract
Background: In invertebrates, the medicinal leech is considered to be an interesting and appropriate model to
study neuroimmune mechanisms. Indeed, this non-vertebrate animal can restore normal function of its central
nervous system (CNS) after injury. Microglia accumulation at the damage site has been shown to be required for
axon sprouting and for efficient regeneration. We characterized HmC1q as a novel chemotactic factor for leech
microglial cell recruitment. In mammals, a C1q-binding protein (C1qBP alias gC1qR), which interacts with the
globular head of C1q, has been reported to participate in C1q-mediated chemotaxis of blood immune cells. In this
study, we evaluated the chemotactic activities of a recombinant form of HmC1q and its interaction with a newly
characterized leech C1qBP that acts as its potential ligand.
Methods: Recombinant HmC1q (rHmC1q) was produced in the yeast Pichia pastoris. Chemotaxis assays were
performed to investigate rHmC1q-dependent microglia migration. The involvement of a C1qBP-related molecule in
this chemotaxis mechanism was assessed by flow cytometry and with affinity purification experiments. The cellular
localization of C1qBP mRNA and protein in leech was investigated using immunohistochemistry and in situ
hybridization techniques.
Results: rHmC1q-stimulated microglia migrate in a dose-dependent manner. This rHmC1q-induced chemotaxis was
reduced when cells were preincubated with either anti-HmC1q or anti-human C1qBP antibodies. A C1qBP-related
molecule was characterized in leech microglia.
Conclusions: A previous study showed that recruitment of microglia is observed after HmC1q release at the cut
end of axons. Here, we demonstrate that rHmC1q-dependent chemotaxis might be driven via a HmC1q-binding
protein located on the microglial cell surface. Taken together, these results highlight the importance of the
interaction between C1q and C1qBP in microglial activation leading to nerve repair in the medicinal leech.
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In the mammalian central nervous system (CNS), micro-
glial cells constitute the resident immune cells, main-
taining the integrity of the nervous system and able to
respond to any kind of brain damage [1]. In healthy
brain, resting microglial cells show a ramified morphol-
ogy [2]. Under pathophysiological conditions, they
rapidly change their morphology and change to amoe-
boid activated microglia. This activation is controlled by
‘on’ or ‘off’ signals [3]. Complement proteins are poten-
tial candidates to exert such ‘on’ signals on microglia
and can induce neuronal cell death [4]. Indeed, the
complement system can be activated by three different
pathways, the classical, the lectin-dependent and the
alternative pathways [4]. Moreover, following human
brain infection or injury, production of complement by
resident cells has been clearly demonstrated to be highly
increased upon activation [5]. Interestingly, C1q, the
first component of the classical complement pathway,
may serve as a reliable marker of microglial activation,
ranging from undetectable levels of C1q biosynthesis in
resident microglia to high C1q expression in activated,
non-ramified microglia. C1q synthesized and released by
activated microglia has been shown to maintain and reg-
ulate microglial activation in diseased CNS tissue [4,6,7].
Thus, C1q plays an important role in microglia regula-
tion after nerve injury.
Unlike mammals, the medicinal leech Hirudo medici-
nalis can fully regenerate its CNS after injury and
restore function of individual neurons [8,9]. For this rea-
son, the leech CNS, which combines simplicity and well
known organization [10], has been an attractive model
in neurobiology for decades. After injury, leech micro-
glia immediately move toward the lesion site. This phe-
nomenon has been shown to be essential to promote
axon sprouting and successful nervous system repair
[11-14]. Leech microglial cells exhibit morphological
changes similar to vertebrate ones in the course of
migration in response to tissue damage [15,16]. In our
laboratory, we were interested to assess the role of C1q
in microglial cell accumulation after leech CNS injury.
We previously characterized, for the first time in an
invertebrate nervous system, a C1q domain-containing
(C1qDC) factor named HmC1q [17]. Of interest, its
involvement in leech microglia recruitment following
experimental injury has been clearly demonstrated. In
order to study its interaction with CNS cells and eluci-
date its role in microglial cell chemotaxis, the recombi-
nant form of HmC1q (rHmC1q) was produced in the
yeast Pichia pastoris. In the present report, we demon-
strate the chemotactic activity of the recombinant pro-
tein on leech microglial cells and we used rHmC1q to
tightly explore its functions in the leech nervous system
following trauma. In vertebrates, C1q has been
demonstrated to exert its chemotactic activity through
C1q receptors expressed on immune cells [18]. Finally,
the interaction between rHmC1q and leech CNS cells
was investigated, allowing the identification of a C1qBP-
related molecule, which was named HmC1qBP, homolo-
gous to the mammalian C1q receptor (alias gC1qR, p32,
p33, C1qBP, HABP1; SF2p32, TAP) [19]. Therefore the
involvement of a C1q domain-containing factor in
microglial activation is demonstrated for the first time
in a CNS.
Methods
Recombinant HmC1q production and purification
Expression vector construction
The cDNA encoding the HmC1q (Genbank accession
number EU581715) [17] was amplified by PCR from
total leech CNS cDNA as template. Amplification was
performed using specific forward (5’gcgccctacgtaatgaaag-
tatttctggaaatcctcgc3’) and reverse (5’taattgcggccgct-
cactttctgcttgcaatt3’) primers containing SnaBI (forward,
bold) and NotI (reverse, bold) restriction sites, respec-
tively, together with the predicted natural signal peptide
sequence (forward, underlined). PCR amplifications were
carried out on a Thermal Cycler (Eppendorf, Hamburg,
Germany) with 150 ng of cDNA in a solution containing
1.25 U of Hot Start Proofreading DNA polymerase
(Accu Prime™ Pfx, Life Technologies, Grand Island,
NY, USA), 0.3 μM of each PCR primer, 1 × DNA poly-
merase manufacturer’s buffer containing deoxyribonu-
cleotide triphosphate (dNTP) in a final volume of 50 μl.
The reaction cycles were performed as follows: 95°C for
2 minutes, followed by 35 cycles of 15 s at 95°C, 30 s at
60°C and 1 minute at 68°C. A single PCR product was
obtained and ligated into the SnaBI and NotId i g e s t e d
pPIC3.5 K vector with T4 DNA Ligase (Life Technolo-
gies, Grand Island, NY, USA) according to the instruc-
tions of the Multi-Copy P. pastoris Expression Kit
manual (Life Technologies, Grand Island, NY, USA).
The plasmid DNA HmC1q/pPIC3.5 K was amplified
into Escherichia coli Top10F’ chemically competent cells
(Life Technologies, Grand Island, NY, USA). Cloning
steps were verified by both strands DNA sequencing
(Eurogentec S.A., Liege, Belgium).
Transformation of P. pastoris strain and screening for
protein expression
The recombinant plasmid HmC1q/pPIC3.5 K (see
above) was linearized with SacI and used to transform
GS115 P. pastoris strain by electroporation according to
the method described in the manufacturer’sm a n u a l
(Life Technologies, Grand Island, NY, USA). Selection
of His+/Mut+ transformants was achieved as previously
described [20]. The recombinant clones were screened
on yeast/peptone/dextrose (YPD) agar plates containing
growing doses of G418 (Geneticin; Life Technologies,
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inserts. A total of 20 clones were inoculated in 10 ml of
buffered glycerol-complex (BMGY) medium (1% w/v
yeast extract, 2% w/v peptone, 1.34% w/v yeast nitrogen
base, 4 μg/ml D-biotin, 100 mM potassium phosphate,
pH 6.0, 1% v/v glycerol) and incubated at 29°C and 225
rpm. After 48 h, cells were pelleted by centrifugation for
2 minutes at 1,000 g at room temperature (RT). The
pellets were gently resuspended in 2 ml of basal mini-
mum medium (BMM) (1.34% w/v yeast nitrogen base, 4
μg/ml D-biotin, 100 mM potassium phosphate, pH 6.0,
0.5% v/v MeOH) and incubated at 29°C and 225 rpm.
After 48 h, the cultures were centrifuged (10,000 g,1 0
minutes, 4°C), and the supernatants were dried under
vacuum to be checked for protein expression by western
blot. The clone corresponding to the highest production
of protein was stored in glycerol at -80°C.
Purification of recombinant protein
Aliquots of supernatants obtained from 32 cultures of 2
ml were centrifuged at 12,000 g for 10 minutes at 4°C,
filtered through a 0.8 μm filter and concentrated until a
1 ml volume (Centricon YM-10, Millipore, Billerica,
MA, USA). Purification was achieved in one step by
reverse-phase high performance liquid chromatography
(RP-HPLC) with a C8 column (250 × 4.1 mm, Grace-
Vydac, Columbia, MD, USA) with a linear gradient of
acetonitrile (ACN) in acidified water (0,1% trifluoroace-
tic acid) from 2% to 32% ACN for 60 minutes at a flow
rate of 1 ml/min. The presence of rHmC1q in the eluted
fractions was checked by western blotting. The RP-
HPLC fraction containing the recombinant protein was
dried under vacuum and stored at -20°C.
For further analyses, the transformed P. pastoris culture
supernatant, the RP-HPLC-purified recombinant protein
and the non-transformed P. pastoris culture supernatant
will be respectively referred to as ‘rHmC1q supernatant’,
‘purified rHmC1q’ and ‘control supernatant’.
Western blotting
Samples (either rHmC1q supernatant, control superna-
tant or purified rHmC1q) were reconstituted in Laemmli
buffer before loading onto a 12% acrylamide running gel
and a 4% acrylamide stacking gel as previously described
[21]. Briefly, migration was carried out using a cathode
buffer (0.6% Tris base, 2.5% taurine, and 0.1% SDS) and
an anode buffer (0.6% Tris base, 2.8% glycine, and 0.1%
SDS). Gels ran at 70 V for 15 minutes and at 120 V for
45 minutes. Separated proteins were transferred to
Nitrocellulose Transfer Membrane Protran BA 83
(Schleicher & Schuell Bioscience, Dassel, Germany) by
electroblotting. After preincubation in blocking solution
(BS) (phosphate-buffered saline (PBS) containing 0.05%
Tween 20 and 2% ovalbumin fraction V) membranes
were incubated overnight at 4°C with either rabbit poly-
clonal anti-HmC1q antibody or preimmune serum (dilu-
tion 1:1,000 in BS). Specific rabbit polyclonal anti-
HmC1q antibodies were raised using a synthetic peptide
corresponding to predicted His
197-Thr
212 region of
HmC1q protein (Agro-bio, La Ferté Saint Aubin,
France) [17]. After three PBS washes, goat anti-rabbit or
anti-mouse IgG antibodies conjugated with horseradish
peroxidase (dilution 1:20 000 in BS) (Jackson Immunor-
esearch, West Grove, PA, USA) were added for 1 h at
RT. The final washes were performed in PBS and immu-
nolabelled proteins were revealed with the ECL Kit
SuperSignal West Pico Chemoluminescent Substrate
(Thermo Fisher Scientific, Rockford, IL, USA) and
Kodak X-Omat LS film (Sigma-Aldrich, St. Louis, MO,
USA).
Leech CNS and microglial cell preparation
All protocols regarding the use of leeches were carried
out in strict accordance with the French legislation and
European Treaty, and were in compliance with the Hel-
sinki Declaration. H. medicinalis adult leeches were
obtained from Ricarimpex (Eysines, France). The leech
nerve cord (CNS) is constituted of 23 metameric ganglia
joined by structures, called connectives, containing the
axonal processes and glial cells [10]. After anesthesia in
10% ethanol at 4°C for 15 minutes, animal CNSs were
dissected out in a sterile Ringer solution (115 mM NaCl,
1.8 mM CaCl2, 4 mM KCl, 10 mM Tris maleate, pH
7.4) under a laminar flow hood After isolation, samples
were placed in three successive baths of antibiotics (100
UI/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml
gentamycin) for 15 minutes and further incubated in
Leibovitz L-15 medium (Life Technologies, Grand
Island, NY, USA) containing 2 mM L-glutamine, 0.6%
glucose and 10 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) (complete medium). The
experimental injury was performed by crushing the con-
nectives between the third and fourth ganglia. Nerve
cords were used for ex vivo recruitment assays, whole
mount immunohistochemistry, fluorescence in situ
hybridization or nerve cell preparation.
For total nerve or microglial cell isolations, nerve
cords treated as indicated above were placed in 35 mm
Petri dishes with 200 μl of complete L-15 medium. Each
ganglion was carefully decapsulated by removing the
collagen layer enveloping the nerve cord with microscis-
sors. Nerve cells, neurons and microglial cells were
mechanically resuspended by gentle scraping (total
nerve cells). After a filtration through 7 μmn y l o nm e s h
as described [17,22], the enriched microglial cell popula-
tion was then collected and centrifuged at 1,000 g for 10
minutes at RT. The cell pellet was resuspended in L-15
medium (100 μl per nerve cord) for migration assays.
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In vitro chemotaxis assays were performed by using the
double-P assay as described by Köhidai and colleagues
with minor modifications [23]. Petri dishes (35 mm)
were filled with 1 ml of a 0.5% agar and 1% gelatin solu-
tion. After drying, two 6 mm diameter wells were made,
each one presenting a parallel individual channel. One
well was filled with 50 μl of purified microglial cells (see
above) and the other one with chemotactic factors or
negative controls reagents. A channel was further cre-
ated perpendicularly to others using a coverslip. By 1 h
later, cells in the chemoattractant containing well were
collected. Either rHmC 1 qs u p e r n a t a n t( 0 . 1 ,1 ,3 ,8a n d
15 μl) or control supernatant (0.1, 1, 3, 8 and 15 μl)
were used as chemotactic factors. For inhibitory chemo-
tactic experiments, cells were preincubated for 1 h at
RT either with rabbit polyclonal anti-HmC1q antibody
or with preimmune serum as negative control (both
1:250); and either with rabbit polyclonal anti-human
C1qBP antibody (1:1,000) or with rabbit IgG isotype as
negative control (1:1,000). The number of migrating
cells was counted on a hemocytometer (three different
counts) under Axioskop microscope (Zeiss, Oberkochen,
Germany). Additional experiments were also performed
with RP-HPLC-purified rHmC1q as chemoattractant in
similar conditions. Experiments were performed in tri-
plicate. The results were expressed as the mean cell
number ± SD. Comparisons between means were made
using the Student’s t test. Statistical differences were
considered to be significant if p was < 0.01.
Ex vivo microglial cell recruitment assays
Ganglia 2, 3, 4 and 5 were dissected from the animal
and pinned in separate plastic 35 mm Petri dishes (Fal-
con 3005, Becton Dickinson, Franklin Lakes, NJ, USA)
coated with silicone rubber (Sylgard 184, Dow Corning
Corp., Midland, MI, USA) and placed in L-15 complete
medium. The following products were respectively
injected (8 μl) inside the connectives separating the
ganglia 3 and 4: PBS; rHmC1q supernatant; rHmC1q
supernatant + anti-HmC1q antibody (dilution 1:5,000);
rHmC1q supernatant + preimmune serum (dilution
1:5,000) or the control yeast supernatant. For injections,
patch pipettes were pulled from borosilicate glass capil-
laries (outer diameter 1.5 mm, Clark GC 150 F-10)
using a two-stage horizontal micropipette puller (model
P-97, Sutter Instrument Co., Novato, CA, USA) (pipette
resistance 3 to 5 MΩ). The connectives were crushed
immediately after injection with fine forceps on both
side of the injection site and the tissues were fixed in
buffered 4% paraformaldehyde, pH 7.4 4 h after the
injection. The Hoechst 33342 (Life Technologies, Grand
Island, NY, USA) fluorescent dye (dilution 1:1,000 in L-
15 medium) was then applied to injured nerve cords for
30 minutes to counterstain the nuclei of microglial cells.
Microglial cells movement in response to these different
injections was then observed with an inverted micro-
scope (DMIRE2, Leica Microsystems, Wetzlar,
Germany).
Immunohistochemistry
In experiments with anti-human C1qBP antibody, ana-
lyses were performed on nerve cords dissected out as
described above and incubated 6 h in complete L-15
medium. They were fixed for 1 h at 4°C, immediately
after dissection (T0) or 6 h (T6h) and 24 h (T24h) after
incubation in complete L-15 medium, in 4% paraformal-
dehyde, washed in PBS, permeabilized by a 24 h-incuba-
tion at RT in 1% Triton X100 in PBS and preincubated
for 8 h at RT in 1% Triton, 3% normal donkey serum
(NDS) and 1% ovalbumin in PBS. Samples were then
incubated overnight at 4°C with specific rabbit polyclo-
nal anti-human C1qBP antibody (1:250) diluted in a PBS
solution containing 1% bovine serum albumin (BSA),
0.05% Triton, 1% NDS and 1% ovalbumin (AB solution).
After three washes with PBS, samples were incubated 1
h at room temperature with anti-rabbit donkey antibody
(Life Technologies, Grand Island, NY, USA) conjugated
to Alexa Fluor 488 (1:2,000 in the AB solution), rinsed
with PBS and finally mounted with Glycergel (Sigma-
Aldrich, St. Louis, MO, USA). Prior to mounting, the
cell nuclei were counterstained by Hoechst dye as pre-
viously described. Samples without the addition of pri-
mary antibody were used as negative control. Slides
were kept at 4°C in the dark until observation, realized
with a Zeiss LSM780 confocal microscope (Zeiss, Ober-
kochen, Germany). We optedt op r e s e n tm i c r o g l i a
nuclei in white for a better display of the results.
Fluorescent in situ hybridization (FISH)
Nerve cords were fixed for 1 h at 4°C in 4% paraformal-
dehyde just after dissection. The 5’ biotin-labeled speci-
f i ca n t i s e n s ep r o b ea n ds e n s ep r o b e( n e g a t i v ec o n t r o l )
were generated from a specific sequence (corresponding
to the nucleotide sequence 154 to 859 of C1qBP mole-
cule; Genbank accession number JN207836). After PCR
amplification and the insertion of the product in
pGEM-T easy vector system (Promega, Madison, WI,
USA), the RNA sequence of interest was obtained by in
vitro transcription using DIG/Biotin RNA-labeling kit
according to the manufacturer’si n s t r u c t i o n s( R o c h e
Diagnostics, Rotkreuz, Switzerland). The hybridization
protocol was performed as previously described [24].
Nerve cords were incubated with a secondary anti-biotin
antibody conjugated to Alexa Fluor 488 (dilution 1:5,000
in PBS) (Life Technologies, Grand Island, NY, USA).
Final rinsing and mounting steps for confocal micro-
scopy observation were performed as described above.
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Total nerve cells isolated as described above from eight
nerve cords were equally distributed (about 10
6 cells per
tube) and kept for 24 h at RT in L-15 medium either
alone or with purified rHmC1q. Then, they were incu-
bated for 30 minutes with the fluorescein-labeled mouse
monoclonal anti-human C1qBP (60.11) antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) (dilution
1:250 in L-15 medium). Nerve cells were then washed
with L-15 medium, centrifuged for 8 minutes at 1,000 g
at 4°C. Cell pellet was resuspended in 500 μl L-15 med-
ium and finally, examined by fluorescence-activated cell
sorter (FACS) (EPICS XL4-MCL, Beckman Coulter,
Diagnostics division, Brea, CA, USA) equipped with an
argon ion laser with an excitation power of 15 mW at
488 nm. Forward scatter (FSC) and side scatter (SSC)
were analyzed on linear scales, while green (FL1) was
analyzed on logarithmic scales. Data acquisition and
analysis were performed using Expo32 software.
Microglial cell protein extraction
Protein extraction was performed by trichloroacetic
acid/acetone precipitation and was resuspended in lysis
buffer (7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopro-
pyl)dimethylammonio]-1-propanesulfonate (CHAPS)).
Protein extracts were desalted by Zeba Desalt Spin Col-
umns, 2 ml (Pierce) following the manufacturer’s guide-
lines. Protein concentration was determined using the
Bradford method (Bio-Rad, Hercules, CA, USA) and
protein extracts were stored at -20°C.
Human C1q biotinylation and streptavidin affinity
purification
The biotinylation of the recombinant human C1q (Pro-
specbio, Rehovot, Israel) was carried out by using the
sulfo-NHS-SS-biotin kit (Thermo Fisher Scientific,
Rockford, IL, USA) according to the manufacturer’s
instructions. Briefly, proteins were biotinylated in PBS
with a 20-fold molar excess for 30 minutes at RT.
Unreacted sulfo-NHS-SS-biotin was removed using the
Zeba Desalt Spin Columns (Thermo Fisher Scientific,
Rockford, IL, USA). Biotinylated human C1q was imme-
diately fixed onto a streptavidin column (Thermo Fisher
Scientific, Rockford, IL, USA), previously equilibrated
with five volumes of PBS 0.1 M. The interaction
between biotin and streptavidin occurred at RT for 10
minutes. Microglia protein extract (800 μg) was added
in the column, incubated overnight at 4°C and rinsed
ten times with PBS 0.1 M. Captured microglial cell pro-
teins were eluted from the streptavidin-agarose with 5%
2-mercaptoethanol/PBS 0.1 M at 30°C for 30 minutes.
Proteins were precipitated in 10% trichloroacetic acid/
acetone at -20°C for 45 minutes, and centrifuged at
13,000 g for 15 minutes. The protein pellet was washed
in cold acetone, air dried and dissolved in Laemmli buf-
fer. Two other columns were used for the negative con-
trols: the first one containing the biotinylated human
C1q with no microglia protein extract and the second
one containing only the microglia protein extract to
evaluate the unspecific reaction between streptavidin
and microglial cell components. Samples were loaded
on a 12% SDS-PAGE gel and analyzed by western blot-
ting using a rabbit polyclonal anti-human C1qBP anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
diluted at 1:5,000 in BS (see above).
Results
Production of recombinant HmC1q in P. pastoris
HmC1q was expressed by the yeast P. pastoris under
control of the methanol-inducible alcohol oxidase pro-
moter and secreted using its natural signal peptide. A
positive clone was selected following the detection of a
signal using the polyclonal anti-HmC1q antibodies by
western blot because of its relevance to the native
HmC1q detection as previously described (Figure 1A,
control) [17]. No significant difference was detected
between the recognition of rHmC1q in the transformed
yeast supernatant and native HmC 1 qr e l e a s e di nt h e
conditioned medium (Figure 1A, positive clone vs con-
trol). The negative control performed with a non-trans-
formed yeast clone did not show any immunoreactive
bands. The presence of three bands on SDS-PAGE
shows slight differences in the recombinant protein, sug-
gesting different levels of glycosylation. The shared
immunoreactivity suggests that rHmC1q has the same
size and migration profile as the native HmC1q. The
expression of rHmC1q was observed up to 4 days with-
out any significant proteolytic degradation (data not
shown). The protein was purified by RP-HPLC and
eluted as the major peak at 10% of acetonitrile (arrow in
Figure 1B). The corresponding molecule (purified
rHmC1q) was then analyzed by western blot by using
the same antiserum and displayed specific immunoreac-
tivity (Figure 1B).
In vitro chemotactic activity of rHmC1q on leech
microglial cells
Native HmC1q has been shown to recruit leech micro-
glial cells in a dose-dependent manner [17]. In the pre-
sent study, the biological activity of the rHmC1q
supernatant was compared to the control supernatant
one using similar volumes in respective chemotaxis
assays (0.1, 1, 3, 8, 15 μl). Freshly prepared leech micro-
glial cells were demonstrated to migrate towards
rHmC1q supernatant also in a dose-dependent manner.
The optimal effect was observed by using 8 μlo f
rHmC1q supernatant while a higher amount (15 μl)
caused a decreased migration of the microglia. This
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activity and has been described for other chemoattrac-
tant factors of leech CNS conditioned medium [22]. Of
interest, similar dose-dependent results were obtained
by using purified rHmC1q (data not shown). The con-
trol supernatant used as negative control did not exert
any significant effect on microglial cell recruitment (Fig-
ure 2A).
In order to maintain a relevant comparison between
rHmC1q and a pertinent negative control, we used the
rHmC1q supernatant (8 μl) as positive control and the
control supernatant (8 μl) as negative control. Chemo-
taxis assays were performed using the rHmC1q superna-
tant and two negative control media (L-15 and control
P. pastoris supernatant) in the presence of blocking anti-
bodies directed against the leech protein (anti-HmC1q)
and the human C1q receptor molecule (anti-C1qBP),
respectively (Figure 2B). Compared to rHmC1q superna-
tant, negative controls did not exert any significant che-
motactic effect (Figure 2B).
Interestingly, the rHmC1q supernatant-mediated
microglial recruitment was inhibited by using rabbit
polyclonal anti-HmC1q antibodies (Figure 2B, black
hatched bars) whereas no significant inhibitory effect
was detected with the preimmune serum (Figure 2B,
gray hatched bars). In addition, no effect was observed
by preincubating cells with polyclonal anti-HmC1q anti-
bodies in negative controls (L-15 medium or the control
P. pastoris supernatant). Finally, the involvement of an
HmC1q binding protein as receptor in mediating micro-
glia chemotaxis in response to rHmC1q was investi-
gated. Pretreatment of microglial cells with rabbit
polyclonal anti-human C1qBP antibodies significantly
abrogated the chemotactic response to rHmC1q (Figure
2B, black dotted bars) whereas no significant inhibitory
effect was detected using rabbit IgG isotype as negative
control (Figure 2B, gray dotted bars). No neutralizing
effect was observed in negative control assays (L-15 or
control supernatant) (Figure 2B).
Taken together, these results clearly indicate that
leech microglial cells specifically respond to rHmC1q in
a dose-dependent manner and strongly suggest that
HmC1q-mediated recruitment is exerted through a
C1qBP-related molecule.
Ex vivo chemotactic effect of rHmC1q on resident
microglial cells in injured nerve cords
The in vitro chemotaxis assays were corroborated by the
ex vivo experiments performed on whole collected and
injured nerve cords. The cell movement was analyzed by
Hoechst dye counterstaining because microglia are the
only circulating resident cells present in connectives
(Figure 2C). The microglial cell migration at the site of
injury was evaluated 4 h after injection of different
molecules in nerve cords, immediately followed by
experimental lesion. In the positive control experiment,
the microglial cell accumulation at the lesion site
strongly increased after nerve injury (Figure 2C, a vs b).
Interestingly, the injection of rHmC1q supernatant
enhanced the microglia recruitment compared to those
obtained in the presence of PBS only (Figure 2C, b vs c)
or in the presence of the control supernatant (Figure
2C, c vs d). Of interest, while preincubation with rabbit
preimmune serum did not have any significant neutra-
lizing effect on rHmC1q-mediated recruitment (Figure
2C, c vs e), the injection of rabbit polyclonal anti-
HmC1q antibodies reduced the rHmC1q supernatant-
mediated chemotactic activity (Figure 2C, c vs f). These
results specifically confirmed the capacity of rHmC1q to
increase ex vivo the microglial cell recruitment following
injury, compared to a normal cell accumulation in the
presence of PBS.
Figure 1 Expression of rHmC1q in the Pichia pastoris yeast host system. (A) Immunodetection of rHmC1q (selected positive clone) by
western blot with the polyclonal anti-HmC1q antibodies is compared with the native HmC1q released in leech central nervous system (CNS)-
conditioned medium (control). Supernatant from non-transformed yeast culture was used as a negative control. (B) Part of the chromatogram of
the yeast culture illustrating the purification of rHmC1q by reverse-phase high performance liquid chromatography (RP-HPLC). The rHmC1q
molecule was eluted at 10% of acetonitrile (see arrow) and was detected by western blot with the polyclonal anti-HmC1q antibody.
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Because of the neutralizing effect observed using anti-
human C1qBP antibodies in chemotaxis assays (see
above), the presence of a potential C1q-binding protein
(receptor-like) was investigated in an expressed
sequence tag (EST) library constructed from total RNA
of nerve cords isolated from adult leeches. A full-length
mRNA sequence for a C1q binding proteins (C1qBP)
related molecule was identified (Genbank JN207836)
encoding a 289-amino-acid sequence (Figure 3A). The
theoretical molecular weight was predicted to be 32,973
Da according to the complete protein sequence. Similar
to mammalian C1qBP, this sequence presents a MAM33
domain (Figure 3A) and contains the mature form as
described for the human C1qBP [19]. Blast-P analyses of
the leech sequence revealed homologies exclusively with
many known C1qBP sequences (Figure 3B) with high
conservation for the MAM33 domain [25,26].
Considering that only C1qBP molecules were matched
from databases, whatever the rate of homology, we
restricted the presentation of the Blast-P analysis to the
highest homology percentages (ranging from 47% to 55%)
in the table (Figure 3B). Multiple alignments were realized
to show the similarities in primary structure of human,
mouse and leech forms (Figure 3C). Interestingly, seven of
t h en i n er e s i d u e se s s e n t i a lfor conformation and ligand
binding properties in the human C1qBP (Glu-89, Arg-122,
Lys-123, Leu-231, Asp-232, Arg-246, Gly-247, Glu-264
and Tyr-268) are conserved in the leech sequence (Glu-
104, Arg-136, Asp-240, Arg-254, Gly-255, Glu-272 and
Tyr-276) [27]. These residues, which suggest comparable
physicochemical features, are indicated in black boxes
(Figure 3A) and are underlined in Figure 3C. The residues
Lys-123 and Leu-231 in the human sequence are replaced
by Thr-137 and Met-239 in the leech one, respectively
(asterisks, Figure 3C). From all these elements, the leech
molecule was named HmC1qBP for H. medicinalis C1qBP.
Localization of HmC1qBP mRNA and protein in leech
microglia
In order to specify the cell expressing the HmC1qBP
transcripts in the leech nervous system, specific fluores-
cence in situ hybridization (FISH)w a sc a r r i e do u to n
injured nerve cords. The transcripts were mainly
Figure 2 Chemotactic effect of rHmC 1 qo nl e e c hm i c r o g l i a
migration. (A) rHmC1q supernatant was compared to control
supernatant using similar volumes in respective chemotaxis assays
(0.1, 1, 3, 8, 15 μl). The diagram illustrates the chemotactic activity of
rHmC1q in a dose-dependent manner. Asterisks denote cell
migration of the indicated sample that is significantly different (p
<0.01) than the corresponding control value. (B) Inhibitory effects
on rHmC1q-mediated leech microglia chemotaxis. Leech microglial
migration was evaluated with either L15 medium, control Pichia
pastoris supernatant or rHmC1q-containing supernatant as
chemoattractant. An inhibitory effect was demonstrated by
preincubation of cells either with rabbit polyclonal anti-HmC1q
antibodies (black hatching in each condition) or with a rabbit
polyclonal anti-human C1qBP (alias gC1qR) antibody (black dots in
each condition). Negative controls consisted of cells preincubated
with rabbit preimmune serum or rabbit IgG isotype respectively.
Asterisks denote cell migration of the indicated sample that is
significantly different (p< 0.01) than the corresponding controls. (C)
Chemotactic effect of rHmC1q on leech microglia in ex vivo assays.
Microglial cells, which are the only circulating resident cells present
in the connectives, were counterstained with Hoechst dye. The
Hoechst dying was observed immediately after crush injury (see
arrows) with injection of phosphate-buffered saline (PBS) (a) or 4 h
after injury with injection of PBS (b) illustrating microglial
accumulation at the lesion site. Injection of rHmC1q increased
microglial cells recruitment (c) compared either to the presence of
PBS only (b) or to control yeast supernatant (d). When tissues were
injected with polyclonal anti-HmC1q antibody (f), the chemotactic
activity of rHmC1q was not observed whereas the corresponding
preimmune serum did not exert any neutralizing effect (e).
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Page 7 of 14Figure 3 Characterization of a C1qBP-related molecule (HmC1qBP) in the medicinal leech. (A) Nucleotide and amino acid sequences of
leech HmC1qBP containing the MAM33 conserved domain are highlighted in light gray (101 to 287). Numbers of nucleotides and amino acids
are indicated on left and right of the sequence, respectively. Residues considered important for correct folding and receptor-ligand interaction in
human and mouse C1qBP are highlighted in black. (B) Blast-P alignments show the most important homologies (ranging from 47% to 55%)
between HmC1qBP and some C1qBP molecules from other species. (C) Multiple alignments between human (NP_001203), mouse (NP_031599)
and leech (Genbank accession number JN207836) C1qBP primary structures show numerous conserved residues (red). Black bars and asterisks
indicate the nine structurally important residues cited above. (D) Fluorescence in situ hybridizations on freshly dissected nerve cord (T0) show
localization of HmC1qBP transcripts in microglial cells (arrows). (D’) The insert corresponds to sense probe as a negative control.
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while no specific signals were detected with sense ribop-
robes used as negative control (Figure 3D’).
Cells containing HmC1qBP protein were investigated by
immunohistochemistry with anti-human C1qBP
antibodies on whole mounted injured nerve cords imme-
diately after dissection, 6 h, or 24 h after lesion (Figure 4).
The microglia recruitment was simultaneously studied by
using a Hoechst dye (white nuclei). Immediately following
the crush (T0), no immunostaining and no accumulation
Figure 4 Immunostaining of leech central nervous system (CNS) using rabbit polyclonal anti-human C1qBP antibodies (green). Ganglia
were analyzed immediately (A),6h(B, C),o r2 4h(D) following injury. Microglial cell nuclei (white) were stained with Hoechst fluorescent dye
to observe cell migration. (A) No anti-C1qBP immunostaining was detected at the lesion site and no microglial accumulation was observed. (B)
At 6 h following injury, positive immunostaining was observed at the site of crush. Simultaneously, microglial cells progressively accumulated at
the lesion site. (C) High magnification image of the injury site. Since all microglia nuclei are shown by Hoechst counterstaining (white), the anti-
C1qBP immunostaining exclusively detects only some microglial cells. (D) At 24 h following injury, the number of microglial cells is much greater
at the lesion site and stronger positive immunostaining is observed. (B’,C ’,D ’) No immunostaining was observed using secondary antibodies
alone as negative controls.
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injury C1qBP staining was detected at the lesion site of
connectives and some microglial cells accumulated at this
site (Figure 4B). Of interest, magnification of the injury
site 6 h after injury showed that the C1qBP staining was
exclusively located in some microglial cells among the
whole recruited microglial population (Figure 4C). There-
fore, the timecourse evolution of C1qBP staining is directly
associated with the progressive migration of microglial
cells. Interestingly, since some microglial cells are still
C1qBP negative it suggests the existence of different states
of reactivity in microglia (Figure 4C). The C1qBP signal is
stronger 24 h after injury at the lesion site and is still cor-
related with the increase of accumulated microglia (Figure
4D). Negative controls performed using the secondary
antibodies alone did not show any signal (Figure 4A’,B’,
D’). This timecourse accumulation of C1qBP positive
microglial cells highly suggests the involvement of C1qBP
in the microglia recruitment.
Identification of a C1qBP molecule on leech microglia
Flow cytometry analyses were then carried out in the
presence of a monoclonal anti-human C1qBP antibody
(Figure 5A-D). A dot plot of leech nerve cells incubated
overnight in L-15 medium was deduced (Figure 5A, on
the right). Among the selected gate that fits on cells
having parameters corresponding to those of microglial
cells, 2.86% of the nerve cells (shown in green on the
dot plot) were autofluorescent (Figure 5A, on the left).
When cells were exposed to the fluorescein-labeled
mouse monoclonal anti-human C1qBP antibody, 46.26%
were positive (Figure 5B, shown in red on the dot plot
and FL1 scale). This antibody recognized a leech protein
localized on the cell surface and did not affect the cell
dot plot overview. However, when the nerve cells were
preincubated overnight with the purified rHmC1q, the
number of immunopositive cells strongly decreased to
5.90% (Figure 5C, on the right for the dot plot and left
for FL1 scale). Indeed, flow cytometry histogram over-
lays clearly showed the fluorescence shift observed when
Figure 5 Flow cytometry analysis of leech nerve cells using
anti-human C1qBP antibody (A-D). (A) On the right side, we
represent a forward scatter (FSC) versus side scatter (SSC) dot plot
for leech nerve cells incubated overnight. Among the cells in the
studied gate, 2.86% of autofluorescence cells are shown on the FL1
scale on the left. (B) On the right, we represent an FSC versus SSC
dot plot for leech nerve cells incubated overnight alone, then
treated with fluorescein-labeled mouse monoclonal anti-human
C1qBP antibody for 30 minutes (dilution 1:250 in L-15 medium). In
the studied gate, 46.26% of the leech nerve cells are stained as
shown on the FL1 scale on the left. The use of the monoclonal
antibody did not affect the dot plot profile of the cells. (C) On the
right, we represent an FSC versus SSC dot plot for leech nerve cells
incubated overnight with 8 μlo fr HmC1q supernatant, then treated
with fluorescein-labeled mouse monoclonal anti-human C1qBP
antibody for 30 minutes (dilution 1:250 in L-15 medium). The
fluorescence rapidly decreased and only 5.90% of the nerve cells are
stained on the FL1 scale on the left. (D) A flow cytometry
histogram overlay shows a shift in fluorescence when the nerve
cells are incubated with anti-human C1qBP antibody (red)
compared to either nerve cells that were previously incubated with
rHmC1q supernatant (blue) or nerve cells alone (gray). These data
are representative of three independent experiments. (E) Western
blot analysis using polyclonal anti-human C1qBP antibodies from
affinity enrichment with biotinylated human C1q. A specific signal
corresponding to a 33-kDa molecule, according to the protein
ladder (L), was detected when biotinylated human C1q was
incubated with leech microglia protein extracts and then eluted on
a streptavidin column (1). No immunopositive signal was observed
when leech microglial protein extracts were eluted alone on
streptavidin column (2) or when biotinylated human C1q was
eluted alone with the streptavidin column (3). No signal was
detected using the secondary antibody alone as a negative control
(data not shown).
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exposed to anti-human C1qBP compared to the cell
incubation with the anti-human C1qBP alone (Figure
5D). These results show that rHmC1q strongly com-
peted for the target protein specifically recognized by
the anti-human C1qBP antibody and suggest that
C1qBP might be the HmC1q binding protein.
Because the above results strongly suggested an inter-
action between HmC1q and a C1qBP, copurification
experiments were performed. Preliminary attempts with
rHmC1q were undertaken. However, because rHmC1q
autoaggregated within some steps of the biotinylation
protocol, human C1q was preferred. Indeed, human C1q
does not present any massive aggregation and was shown
to exhibit a chemotactic effect on leech microglia [17],
similarly to rHmC1q. Once biotinylated, human C1q was
incubated with leech microglia protein extracts. Follow-
ing elution on an activated streptavidin column, the
interactants of C1q were analyzed by western blotting
using polyclonal anti-human C1qBP antibodies (Figure
5E). The polyclonal anti-human C1qBP antibodies speci-
fically recognized a unique 33-kDa molecule (Figure 5E,
lane 1), which corresponds to the predicted molecular
weight of HmC1qBP. In the first negative control, when
microglia protein extracts were incubated on a streptavi-
din column alone (Figure 5E, lane 2) no signal was
obtained, showing that leech microglial proteins cannot
recognize streptavidin. In the second negative control,
when the sulfo-NHS-SS-biotin-labeled human C1q was
loaded alone on streptavidinc o l u m n( F i g u r e5 E ,l a n e3 ) ,
no immunoreactivity was detected, indicating that anti-
human C1qBP antibodies do not react with the human
C1q. Therefore, these results gave evidence of a specific
interaction between human C1q and a C1q-binding pro-
tein present in leech microglia protein extract.
Discussion
In mammals, microglial cells are regulators of tissue
homeostasis and are involved in pathological processes
orchestrating tissue remodeling. They are currently con-
sidered to function as sensors in the brain [28]. Among
the mediators expressed by microglial cells and neurons,
the subunit C1q belonging to C1 complement factor
seems to be a key molecule in neuroinflammatory dis-
eases [29-33]. This complement protein is involved in a
large array of vital functions such as the modulation of
various immune cells, clearance of apoptotic cells and
unwanted synapses, phagocytosis and chemotaxis
[34-36]. In several neurodegenerative diseases, tight
interactions between C1q and microglial cells may be
crucial in the regulation of neuroinflammation [37]. C1q
biosynthesis rapidly increases when microglial cells are
activated. C1q might be thus considered as a reliable
marker for microglia activation.
Of interest in vertebrates, soluble C1q appears to be a
potent chemoattractant factor. Indeed, it recruits human
immature dendritic cells (DC), neutrophils, eosinophils
and mast cells [18,38] through a C1q receptor-dependent
mechanism [18,38]. The globular C1q-binding proteins
(also called C1qBP, gC1qR, p32, p33 or TAP) interact
with the globular heads of C1q and participate in C1q-
mediated chemotaxis of human neutrophils [39], human
eosinophils [40] and murine mast cells [19]. However, a
specific chemotactic activity of C1q through a C1qBP has
not previously been reported for mammalian nerve cells.
In the medicinal leech, previous reports have demon-
strated that microglial cell recruitment is essential for
efficient repair of injured CNS tissue [14]. In this origi-
nal report we elucidate the role of HmC1q as a chemo-
tactic factor by using a recombinant protein and by
identifying a C1q-binding protein (HmC1qBP) as a
potential receptor present on microglial cells. This study
in the medicinal leech is the first evidence of the inter-
action between C1q domain-containing protein and
C1qBP enabling microglia recruitment in injured CNS.
In the first part of the present study, recombinant
HmC1q was produced in the yeast P. pastoris, an organ-
ism that can be easily manipulated at the molecular
genetic level and may express proteins at high levels,
intracellularly or extracellularly. In addition, P. pastoris
performs ‘higher eukaryotic’ protein modifications, such
as glycosylation, disulfide bond formation, and proteoly-
tic processing, compared to bacteria such as Saccharo-
myces cerevisiae or baculovirus [41]. The selected clone
studied in this report was immunopositive using anti-
HmC1q antibodies, with three distinct immunoreactive
bands located in the region corresponding to that of
native HmC1q (32.6 kDa). As usually observed in
recombinant protein production, there was a slight shift
in the final recombinant protein size that can be easily
caused by differences in the number and type of added
sugar units. Indeed, P. pastoris is able to add both O-
linked and N-linked carbohydrate moieties to secreted
proteins. Of interest, the recombinant HmC1q exhibited
chemotactic activity toward leech microglial cells similar
to that of HmC1q-containing medium, previously shown
to act as human C1q [17]. A similar dose-dependent
chemotactic effect was observed with rHmC1q superna-
tant as well as with purified rHmC1q (data not shown)
and, in these two cases, microglial cell recruitment was
specifically neutralized when cells were preincubated
with anti-HmC1q antibodies. It must be underlined that
(i) microglial recruitment was normal when the cells
were preincubated with rabbit preimmune serum, and
(ii) control yeast supernatant, without rHmC1q, did not
exhibit any chemotactic effect. Therefore, this study
shows that the chemotactic effect is dependent on the
presence of rHmC1q.
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effect only on a fraction of microglial cells, suggesting
the existence of a subpopulation that is HmC1q-depen-
dent. We have recently shown that crushed nerve cord-
conditioned medium contains another chemoattractant
factor, homologous to the mature form of interleukin
(IL)-16 and named HmIL-16, which also promotes
microglial cell migration [22]. As observed for HmC1q,
HmIL-16-dependent recruitment is limited to some
microglial cells. Therefore, in leech, the involvement of
several activation and migration signals acting on differ-
ent subsets of microglial cells at the lesion site could be
taken into account as suggested for mammals [3,42].
Additional ex vivo experiments in injured nerve cords
have clearly shown that the recombinant HmC1q con-
serves its functional properties in the whole nerve cord.
Indeed preinjection of rHmC1q into injured nerve cords
enhances microglial cell migration at the lesion site
(rHmC1q vs PBS) and this accumulation is specifically
inhibited by anti-HmC1q antibodies but not by preim-
mune serum. Taken together, these results emphasize
the in vitro and ex vivo chemotactic activity of rHmC1q
in the recruitment of resident microglial cells present in
leech CNS. In order to specify the in vitro chemotactic
mechanisms of rHmC1q on microglia, we first used
antibodies against a potential C1q receptor as described
in the literature [43]. Under our experimental condi-
tions, HmC1q-dependent cell accumulation was abro-
gated after cell preincubation with the anti-human
C1qBP antibody, but not with the isotype control.
Therefore it must be assumed that this HmC1q-depen-
dent chemotaxis involves a homolog of human C1q-
binding protein (C1qBP, alias gC1qR).
To reinforce this observation, in the second part of
the study, attempts were undertaken to characterize the
potential receptor of HmC1q on the surface of leech
microglial cells. This goal was achieved through several
experimental approaches: the identification of a C1qBP-
related sequence in leech CNS EST databases, the locali-
zation of the leech form of C1qBP, binding competition
of HmC1q for the protein specifically recognized by an
anti-C1qBP antibody, and the purification of this bind-
ing protein to a biotinylated human C1q.
A 33 kDa C1qBP-related molecule was characterized
from leech CNS EST databases. This sequence contains
a MAM33 domain, which is attributed to an acidic pro-
tein of the mitochondrial matrix involved in oxidative
phosphorylation and specifically related to the human
complement receptor C1qBP [44]. The leech molecule
named HmC1qBP exhibits strong similarities with verte-
brate and invertebrate known C1qBPs. The comparison
between the leech form of C1qBP (HmC1qBP) and the
human and mouse ones shows the presence of key resi-
dues described as essential for receptor folding and
ligand binding properties [27] Most of them (seven out
of nine) are perfectly conserved. The residues Thr-137
and Met-239 in the leech sequence are respectively
related to residues Lys-123 and Leu-231 in the human
one, showing comparable physicochemical features.
Interestingly, the fluorescence in situ hybridization led
to us specifically locating HmC1qBP mRNA in micro-
glial cells. Following lesions in the leech nerve cord, a
timecourse analysis of C1qBP immunostaining was per-
formed using anti-human C1qBP antibodies in order to
localize the HmC1qBP protein. The accumulation of
microglia was simultaneously observed using Hoechst
dye because only microglial cells are able to circulate
inside the connectives.
Immediately after a lesion, no specific C1qBP staining
was observed in the damaged connectives while no
microglial cells accumulated at the crush site. Of inter-
est, over the timecourse analysis (0, 6 and 24 h following
the crush) the C1qBP molecule was progressively
detected at the lesion site. This increase in cell
HmC1qBP staining was exclusively observed where
Hoechst-dyed microglia accumulated. Analysis of the
lesion site with high magnification revealed, at 6 h fol-
lowing the lesion, that HmC1qBP protein is only present
in microglia. Importantly, only a part of the numerous
Hoechst-dyed recruited microglial cells are HmC1qBP
positive. Therefore, these data suggest that HmC1qBP
c o u l db ei n v o l v e di ns p e c i f i cr e c r u i t m e n to faw e l l
defined microglial cell subpopulation whose chemotaxis
is mediated by recognition between HmC1q and
HmC1qBP.
Subsequent competition binding assays analyzed using
flow cytometry revealed that recombinant HmC1q may
share the same protein target recognized by the anti-
human C1qBP antibody on the surface of leech micro-
glial cells. Indeed, whereas the anti-human C1qBP anti-
body alone was found to bind to at least 46% of
microglial cells, preincubation with rHmC1q markedly
decreased the percentage of cells with specific fluores-
cence to 5%. This observation shows that rHmC1q acts
as a competitor for anti-C1qBP antibodies, indicating
that both molecules bind to the same ligand.
To definitively demonstrate that a C1qBP is implicated
in leech microglial cell recruitment, a copurification
strategy was undertaken using biotinylated human C1q.
From the specific complexes eluted, a 33-kDa molecule
was specifically detected by western blotting. Interest-
ingly, this product presented the same molecular weight
as the predicted HmC1qBP protein. This result, in con-
junction with the in vitro competitive effect between
HmC1q and anti-human C1qBP antibodies, confirms
that HmC1q is able to bind to a C1qBP-related molecule
in leech microglia. Therefore the present report demon-
strates that HmC1qBP has structural and functional
Tahtouh et al. Journal of Neuroinflammation 2012, 9:37
http://www.jneuroinflammation.com/content/9/1/37
Page 12 of 14analogies with its human counterpart. Though consis-
tent data are provided in this report that clearly demon-
strate the involvement of a C1q-binding protein acting
as a receptor for HmC1q, the involvement of other
potential receptors in microglial cell recruitment during
nerve injury cannot be excluded and requires further
experiments.
Indeed, in mammals, the C1qBP molecule interacts
with the globular heads of C1q [19,45] whereas the
other type of C1q-binding protein, the cC1qR (calreticu-
lin) binds to the collagenous portion of C1q [46].
Human C1q has been shown to be a chemotactic factor
for human immature dendritic cells. This migration is
mediated through ligation of both C1qBP (gC1qR) and
cC1qR [18,47]. As the collagen-like sequence is present
in HmC1q [17], additional experiments will investigate
the existence of a cC1qR-related molecule that might be
involved in HmC1q-dependent microglia recruitment.
Conclusions
Recombinant HmC1q was demonstrated to exert effi-
cient chemoattractant activity in vitro and in injured
nerve cords. In addition, HmC1q was shown to act on a
microglial cell subpopulation through HmC1qBP. In
mammals, such an interaction was identified in dendritic
cells, but has never been shown in nerve cells. In sum-
mary, the production of rHmC1q and the evidence of
the involvement of HmC1qBP contribute to a better
understanding of microglial activation leading to leech
nerve repair. These data from the leech CNS highlight
C1q domain-containing factor functions in the integrity
of the CNS, as recently suggested in mammals [36,48].
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